Navigation Links
Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation
Date:10/31/2012

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Fish & Richardson scored a major victory for San Diego based Volcano Corporation in a patent trial regarding medical device technology used to diagnose heart problems.  After less than 90 minutes of deliberation, a federal district court jury in Delaware found that Volcano did not infringe two patents asserted by St. Jude Medical Inc. and that another two St. Jude patents were invalid.  A fifth St. Jude patent was declared not infringed by the court on the eve of trial.  The lawsuit, filed in 2010 by St. Jude, sought to shut down Volcano's rapidly growing cardiac Functional Management business.  The verdict was delivered on October 19, 2012 and was initially subject to an agreement by the parties not to issue press releases.

The Fish team was led by Frank Scherkenbach with assistance from principals Todd Miller, Michael Rosen, Michael Amon, Thomas Halkowski, and John Farrell and associate Corrin Drakulich.  St. Jude was represented by DLA Piper.

Volcano and St. Jude are competitors in the fast-growing pressure sensing guide wire business.  These wires are six feet long and two hairs thick and include a microscopic pressure-sensing chip.  Functional Management is a guide wire based technology that analyzes pressure and flow parameters from inside of the vessel.

"We are very pleased to deliver this significant victory for Volcano in its David vs. Goliath like lawsuit," stated Todd Miller of Fish & Richardson.  "Volcano is now free to once again focus on bringing its life saving technologies to patients."

The jury found that St. Jude Medical patents 6,112,598 (a sensor mount patent) and 6,248,083 (a calibration patent) were not infringed and patents 5,938,624 and 6,196,980 (connector patents) were invalid. 

In a separate trial heard the following
'/>"/>

SOURCE Fish & Richardson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keynote Presentation at Upcoming International Microbiology & Genomics Meeting to Highlight Ability of Pressure BioSciences Patented PCT Platform to Improve Testing for Biological Threat Organisms, Human Infectious Diseases, and Contaminated Food P
2. Johnson & Johnson Postpones Medical Devices & Diagnostics Review
3. Health Partner Sauna & Generation Rescue Partner to Bring Awareness of Infrared Sauna Benefits to Autism
4. The Informex Global Pharma Sourcing Event Announces New Sponsor & Speakers
5. Anesthesia Equipment and Associated Peripherals: Advanced, Patient-Friendly Devices Will Sustain Market Growth in Europe, States Frost & Sullivan
6. Johnson & Johnson to Host Medical Devices & Diagnostics Review
7. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
8. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
9. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
10. Johnson & Johnson Announces Plans to Establish Innovation Centers
11. Talyst Holds User Group Meeting & Two-Day Customer Education Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... 11, 2014 Patient engagement has become ... organizations are turning to an assortment of marketing ... part of this evolving approach to patient engagement, ... and engage patients throughout their experiences with a ... By mapping the patient journey and employing a ...
(Date:7/11/2014)... 11, 2014 The consumer marketing playbook ... industry sectors to better identify winning tools and ... engage with and understand consumers, as new technologies ... critical purchasing decisions. According to ... one area where organizations can observe a deep ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
(Date:7/12/2014)... (PRWEB) July 12, 2014 With prom ... dress manufacturer and retailer, is ready to showcase its ... its new collection of evening dresses in its online ... to 67% off) for these elegant gowns. According to ... an end on July 26, 2014. , He ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Wright & Schulte ... DePuy Orthopedics , Inc., a subsidiary of Johnson & Johnson, ... suffers chronic pain after receiving a metal-on-metal DePuy Pinnacle hip ... to remove the artificial hip implant. The DePuy hip lawsuit ... Northern District of Texas (Case No. 3:14-cv-2427) where DePuy ...
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... Utah (PRWEB) July 12, 2014 Utah ... types of startups, with awards being bestowed to companies ... spotlighted Utah’s outstanding entrepreneur community with recognition for new ... sustainable model with incoming revenue. , 25 Under 5 ... the state that are under 5 years old. Award ...
(Date:7/12/2014)... A recent article released by Seattle's well ... suggestions for those seeking cosmetic surgical procedures in summer ... and the heat begins to enliven the rainy Pacific Northwest, ... realizing that they didn’t work out as much during the ... a sudden surge of people eager to look their best ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... , , YSA and ... , , WASHINGTON, Aug. 10 ... the second year to offer UnitedHealth HEROES grants to youth-led ... Educators, service-learning coordinators, and students in the health professions are ...
... Long-standing liver disease has long been recognized to result ... various international studies, the overall incidence has varied from ... However, the reason for this is poorly understood. With ... and offering complete cure and long-term survival, bone disease ...
... age than is normal, researchers note , MONDAY, Aug. 10 ... the attacks on the Twin Towers on 9/11 may be ... blood. , Notably, half of the cases identified among law ... is usually a disease of the elderly. , "This ...
... , , , , ... now participate in the advanced stuttering treatment program at Hollins Communications ... at a substantially reduced cost through 2009 thanks to new stuttering ... , HCRI,s scholarship program is designed to broaden accessibility ...
... RONKONKOMA, N.Y., Aug. 10 NBTY, Inc. (NYSE: ... marketer of nutritional supplements, today announced that it will web cast the ... the Canaccord Adams Global Growth Conference in Boston on Thursday, ... to be web cast live on the Company Web site, ...
... , ROCHESTER, N.Y., Aug. 10 Your sleeping problems ... as Fibromyalgia (FM), and Chronic Fatigue Syndrome (CFS). But it can ... , , Recent studies show that ... review written by Professor Mark Opp from the University of Michigan ...
Cached Medicine News:Health News:Youth Find Innovative Solutions to Leading Health Threat 2Health News:Youth Find Innovative Solutions to Leading Health Threat 3Health News:Youth Find Innovative Solutions to Leading Health Threat 4Health News:9/11 Responders May Be At Raised Myeloma Risk 2Health News:9/11 Responders May Be At Raised Myeloma Risk 3Health News:Hollins Communications Research Institute Announces More Stuttering Therapy Scholarships 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 3Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 2Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: